In eukaryotes, fatty acid synthase (FAS) is the enzyme responsible for synthesis of palmitate, the precursor of long-chain nonessential fatty acids. FAS is up-regulated in a wide range of cancers and has been suggested as a relevant drug target. Here, two independent approaches are taken toward knocking down FAS and then probing its connection to tumor cell proliferation. In one approach, Orlistat, a drug approved for treating obesity, is used as a potent inhibitor of the thioesterase function of FAS. In a separate strategy, the expression of FAS is suppressed by targeted knock-down with small interfering RNA. In both circumstances the ablation of FAS activity causes a dramatic down-regulation of Skp2, a component of the E3 ubiquitin ligase that controls the turnover of p27 Kip1 . These effects ultimately tie into the retinoblastoma protein pathway and lead to a cell-cycle arrest at the G 1 /S boundary. Altogether, the findings of the study reveal unappreciated links between fatty acid synthase and ubiquitin-dependent proteolysis of cell-cycle regulatory proteins.
INTRODUCTION
enzyme and inhibits fatty acid synthesis (14) . The inhibition of FAS by either cerulenin or c75 can suppress tumor cell proliferation and in some cases can induce tumor cell apoptosis (14) (15) (16) (17) (18) (19) (20) .
These observations support the contention that FAS is a relevant drug target in oncology.
However, both cerulenin and c75 are now known to have other molecular targets (21) (22) (23) , so searches for additional antagonists of FAS with better selectivity and distinct mechanisms of action are certainly warranted.
We recently reported that Orlistat, a drug approved for treating obesity, is a rather potent and selective inhibitor of FAS in prostate carcinoma cells (24) . The drug elicits its effects by inhibiting the thioesterase domain of FAS, which is responsible for releasing palmitate from the enzyme's acyl carrier protein. By virtue of this activity, Orlistat was able to slow the growth of xenograft tumors of PC-3 prostate carcinoma cells in mice (24) . The objective of the present study was twofold. First, we sought to use an independent strategy to confirm that the antiproliferative effects of Orlistat result from inhibition of FAS. Second, we sought to elucidate the mechanism by which a FAS blockade interferes with tumor cell proliferation. Both Orlistat and siRNA targeting FAS cause a dramatic down-regulation of Skp2, a component of an E3-ligase ubiquitin ligase that tags p27
Kip1 for degradation by the proteasome. These findings mechanistically connect two biochemical pathways being explored as drug targets in cancer, fatty acid biosynthesis, and ubiquitin-dependent proteolysis.
Purification and identification of serine hydrolases by avidin-biotin affinity
chromatography and MALDI-TOF mass spectrometry. Serine hydrolases were identified using the FP-PEG-biotin probe (26) . Briefly, cell lysates were preabsorbed with avidin-agarose to reduce nonspecific binding of proteins during purification. Lysates were labeled with FP-PEG-biotin (5 µM) at room temperature for 1 h, after which proteins were separated from unincorporated FP-PEG-biotin by gel filtration on Nap 25 columns. Following the addition of 0.5% SDS, the eluate was boiled for 10 min to denature proteins. Samples were diluted with 50 mM Tris (pH 7.5) and 150 mM NaCl and absorbed with avidin-agarose for 1 h at room temperature. Avidin-agarose beads were pelleted by centrifugation and washed eight times with 50 mM Tris (pH 7.5), 150 mM NaCl, and 1% Tween 20. Labeled proteins were eluted with 2X sample buffer, resolved by 10% SDS-PAGE, and detected by silver staining. Specific bands were extracted and subjected to in-gel trypsin digestion and peptide mass fingerprinting with MALDI-TOF using methods previously described (27, 28) .
Inhibition of serine hydrolase activity with Orlistat. Orlistat was extracted from Xenical  capsules (Roche, Indianapolis, IN) by solubilizing each pill in 1 ml ethanol. Insoluble product was removed by centrifugation (14,000 rpm for 5 min). The supernatant yielded a solution of Orlistat (250 mM), which was aliquoted and stored at -80°C. Soluble cell extracts (40 µl) were incubated with Orlistat (0-1 µM) for 20 min prior to FP-PEG-TAMRA addition.
Lysates were labeled with FP-PEG-TAMRA, and reactions were terminated and processed as described above. The final concentration of DMSO or ethanol in each reaction was 10%.
Gene silencing using siRNA. FAS siRNA sequences corresponding to 5′ CAA CTA CGG CTT TGC CAA T (nucleotides 6213-6231), 5′ GCA ACT CAC GCT CCG GAA A (nucleotides 6657-6675), 5′ GCC CTG AGC TGG ACT ACT T (nucleotides 6146-6164) and 5′ Orlistat and anti-FAS siRNA block fatty acid biosynthesis.
We sought an independent means of inhibiting FAS to solidify the role of this enzyme in regulating tumor cell proliferation. Therefore, we compared Orlistat and siRNA targeting FAS for the ability to knock down the enzyme's activity in MDA-MB-435 mammary carcinoma cells (Fig. 3) . As expected, Orlistat was without effect on the level of FAS ( A FAS blockade alters the key regulatory steps in the retinoblastoma protein pathway.
We examined the effects of a FAS blockade on key regulatory steps in the retinoblastoma protein (Rb) protein pathway, a primary regulator of the G 1 /S transition (30) . This analysis (32) . The effect of a concentration range of Orlistat on each of these parameters was measured by Western blotting (Fig. 4A ).
Orlistat reduced phosphorylation of the Rb protein, up-regulated p27 Kip1 , and down-regulated Consequently, we conclude that inhibition of FAS acts upstream of the proteasome to control p27 Kip1 levels and ultimately block cell-cycle progression. The mechanistic connections between the FAS blockade by Orlistat and reductions in Skp2 are the subject of current investigation.
The observations in this report are different from prior work in which cerulenin and c75
were employed as FAS inhibitors. These compounds block both G 1 /S and G 2 /M progression (16, 19, 36 It is now clear that several avenues for antitumor therapy converge at the G 1 /S transition.
Recent work indicates that Skp2 is one of the important G 1 /S regulatory points because it is necessary for ubiquitin-dependent degradation of p27 Kip1 (32) . Consequently, Skp2 is a positive regulator of cell-cycle progression. In fact, Skp2 has even been suggested as a potential drug target (37) , an idea that is significantly strengthened by the recent observation that Skp2 levels are associated with reduced survival in prostate cancer (38) . The present study shows that a FAS blockade ultimately decreases Skp2 levels. Therefore, FAS represents an upstream leverage point for targeting Skp2. Identifying and understanding the mechanism and molecular players that make this connection is an important future direction. Orlistat
